Abstract 15144: The Heartline Experience: Can Digital Health Technology Trials Achieve Long-Term Participant Engagement?
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Digital health technologies can potentially streamline clinical research and reach broad and diverse populations, yet they often fall short to achieve long-term participant engagement. Research Question: Can long-term participant engagement in a large, direct-to-participant randomized trial using an entirely decentralized trial platform be achieved? Methods: Heartline (www.heartline.com) was designed to test the impact of a mobile app-based heart health program with the electrocardiogram (ECG) and Irregular Rhythm Notification (IRN) features on Apple Watch for early diagnosis, treatment, and outcomes of atrial fibrillation (AF). The custom app collected electronic patient-reported outcomes (ePROs) and incorporated engagement strategies based on behavioral science principles and features relevant to the target study population, including a simple interface and actions, weekly curated health education, and points-based incentives. Participants who received an IRN from their Apple Watch were prompted to take an ECG and follow up with their healthcare provider (HCP). Results: From 02/2020 to 12/2022, Heartline enrolled 34,245 US participants ≥65 years of age. To date, 80% and 76% of the study population used the app at least monthly after 1 and 2 years, with weekly engagement rates of 68% and 66%, respectively ( Figure ). ePRO response rates were 88% at 1 year and 91% at 2 years. Of those receiving an IRN, 85% took an ECG recording and 71% reported follow up with their HCP. Conclusions: The Heartline study achieved high rates of sustained, longitudinal engagement, with >75% of the study population remaining engaged over 2 years and >90% completing ePROs, representing substantially higher engagement rates than prior remote digital health studies. A combination of strategies was used to promote engagement in Heartline. Further work to identify the key drivers of engagement will inform future decentralized trials and digital therapeutics.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Abstract 15144: The Heartline Experience: Can Digital Health Technology Trials Achieve Long-Term Participant Engagement?
- Date Crossref
- 07/11/2023
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Janssen (United States) pays non établi dans la noticeEntreprise
-
The University of Texas Southwestern Medical Center pays non établi dans la noticeÉtablissement de santé
-
Scripps Research Institute pays non établi dans la noticeOrganisation à but non lucratif
-
Jacobs (United States) pays non établi dans la noticeEntreprise
-
West Health pays non établi dans la noticeÉtablissement de santé
-
Kansas City Heart Rhythm Institute pays non établi dans la noticeÉtablissement de santé
-
Janssen Scientific Affairs (United States) pays non établi dans la noticeEntreprise
-
Apple (United States) pays non établi dans la noticeEntreprise
-
Saint Luke's Hospital pays non établi dans la noticeÉtablissement de santé
-
Janssen Rsch & pays non établi dans la noticeInstitution
-
Univ of Texas Southwestern Med Cntr Div of Cardiology pays non établi dans la noticeUniversité ou école supérieure
-
Scripps Rsch Translation Institute pays non établi dans la noticeStructure de recherche
Janssen (United States), The University of Texas Southwestern Medical Center et Scripps Research Institute, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.